GSK

GSK plc

Healthcare · $99.6B market cap

We can't put a fair value on GSK right now. It looks like a preferred share, note or other security rather than ordinary common stock. The figures we receive belong to the parent company, so they can't value this security.

Business quality

1 of 5 clear the 10% bar. What are the Big Five?

Earnings per share growth0.1% a year✗

Equity per share growth4.8% a year✗

Sales growth1.4% a year✗

Free cash flow growth2.2% a year✗

Return on invested capital12.2%✓

Follow GSK

Track it on your watchlist and see the full analysis. Free.

Create a free account

Superinvestors

6 of the investors we track hold GSK. In Q2 2026, 1 added and 2 trimmed. Who we track

Dodge & Cox Funds

Dodge & Cox Funds · as of Q2 2026

$2.5B

48,197,514 shares

Kahn Brothers Group

Kahn Brothers Group · as of Q2 2026

$8.9M

160,982 shares

Hillman Capital Management

Hillman Capital Management · as of Q2 2026

$4.8M

92,383 shares

Tweedy Browne

Tweedy Browne · as of Q2 2026

$4.3M

81,527 shares

Richard Pzena

Pzena Investment Management · as of Q2 2026

$1.3M

24,507 shares

Show all 6 holders

Sarah Ketterer

Causeway Capital Management · as of Q2 2026

$375K

7,163 shares

Moves in Q2 2026

Added: Richard Pzena

Trimmed: Sarah Ketterer, Dodge & Cox Funds

About GSK plc

GSK plc, a global pharmaceutical entity founded in 1715 and headquartered in Brentford, United Kingdom, dedicates its efforts to the research, development, and manufacturing of a wide array of medical solutions. Until May 2022, the company was known as GlaxoSmithKline plc. Its primary objective is to prevent and treat illnesses by producing both vaccines and a comprehensive range of specialty and general medicines…

Drug Manufacturers - General

Fair value and Payback Price are estimates from the company's reported financials, not investment advice. Prices as of the close of Oct 3, 2026. How the Payback Price works

Verdict

Business quality

Superinvestors

About GSK plc